Key takeaways
- KLOW is a seller name for a pre-mixed vial of GHK-Cu, BPC-157, TB-500 and KPV. It is not a compound, and labels can list more than the four.
- We found no published study, in any species, and no registered trial that gave the four together (PubMed and ClinicalTrials.gov, 21 Nov 2026).
- Each component has its own evidence. In the studies we cite: small topical skin studies for GHK-Cu, small human studies and animal work for BPC-157, animal and cell studies for TB-500, and mouse and cell studies for KPV.
- In November 2026 Australia’s TGA found no detectable TB-500 in two KLOW products from one brand, identified in a New South Wales police investigation, although their labels listed it.
- Regulators treat the components one by one. WADA names BPC-157 and TB-500 as prohibited at all times; it does not name KPV or GHK-Cu, and says a peptide not specifically named “may still be prohibited”.
01What is in KLOW?
Four peptides in one vial. KLOW is a product name, not a molecule.
Sellers use the name KLOW for a single vial that mixes four peptides: GHK-Cu, BPC-157, TB-500 and KPV. No regulator or peer-reviewed source defines the mix or says how much of each it holds, and labels can list more than the four. One example is on public record. In November 2026 Australia’s regulator, the TGA, published laboratory results for products from one brand, identified in a New South Wales police investigation. It recorded that the brand’s KLOW was “labelled as containing GHK-Cu, BPC-157, TB 500, KPV, and vitamin B12”.
The label on each card is the kind of study we cite for that component.
GHK-Cu
The copper(II) complex of glycyl-L-histidyl-L-lysine, a three-amino-acid peptide isolated from human plasma in 1973. The human studies we cite applied it to the skin.
BPC-157
A synthetic 15-amino-acid peptide. FDA staff counted five small clinical studies; no peer-reviewed randomised trial is in PubMed (21 Nov 2026).
TB-500
In FDA and HHS documents, a synthetic seven-amino-acid fragment of the protein thymosin β4. FDA staff found no clinical studies of it.
KPV
A three-amino-acid peptide, lysine–proline–valine. FDA staff found no clinical studies or human exposure data.
02What is the difference between GLOW and KLOW?
One peptide. KLOW is the GLOW mix with KPV added.
| Question | GLOW | KLOW |
|---|---|---|
| Listed components | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| What the fourth component adds to the published record | No fourth component | Mouse and cell studies of KPV on its own; FDA staff found no clinical studies or human exposure data for KPV |
| Identities a lab report has to confirm | Three | Four |
Side by side, with each component’s status: GLOW vs KLOW. GLOW has its own page: what is the “GLOW peptide”?
03What colour is KLOW, and where does any blue come from?
Any blue comes from one component: the copper in GHK-Cu.
We found no published measurement of the colour of a KLOW vial, so this answer rests on the chemistry of the components. FDA’s 2026 reviews describe BPC-157, TB-500 and KPV as white to off-white powders. GHK-Cu holds a copper(II) ion. A 2021 study measured the main visible absorption band of GHK-Cu at 606 nm in a neutral buffer. Light near 600 nm is orange, and a solution that absorbs orange and red light looks blue.
The colour shows that copper(II) is present in some form. It cannot confirm that any of the four peptides is there, how pure the material is, or how much a vial holds. The full chemistry: why is GHK-Cu blue?
04What has each of the four components been studied in?
Each row is graded on its own. None of it transfers to a mixed vial.
| Component | Design of the studies we cite | What was measured | Limit |
|---|---|---|---|
| GHK-Cu | Small topical skin studies in people (T2), among them a 2006 randomised trial of a skin-care regimen after laser resurfacing that 13 patients completed | In that trial: redness, wrinkles and skin appearance over 12 weeks, scored by software and blinded evaluators, plus a patient questionnaire | The objective measures found no difference between groups; patients using GHK-Cu rated their skin quality higher. A skin study says nothing about a mixed vial |
| BPC-157 | Six small human studies, most without a control group (T2): five reviewed by FDA staff, and a 2026 report of three patients. No peer-reviewed randomised trial is in PubMed (21 Nov 2026) | Among the measures FDA’s 2026 review reports: plasma levels in two studies, and adverse events | FDA staff: the studies “were of short duration, had small sample sizes”, and there is “insufficient clinical safety information to characterize the safety profile” |
| TB-500 | A 2026 rat study: 32 rats, eight per group, given BPC-157, TB-500, both or neither (T3) | The load a repaired Achilles tendon held before failing, and microscope scores of the tissue, at four weeks | The paper calls its material “synthetic thymosin beta-4 (TB-500)”; FDA staff write that thymosin β4 and TB-500 “are not the same substance”. In people, FDA staff found no clinical studies or human exposure data; a 2026 report describes three patients given it with other agents, without a control group; a placebo-controlled trial, NCT07487363, is recruiting |
| KPV | A 2008 study in mice, with two chemically induced forms of colitis, and in three human cell lines (T3, T4) | Inflammatory signalling inside the cells, the signalling proteins they released, and inflammation in the mouse colon | FDA staff found no clinical studies or human exposure data, identified no pharmacokinetic study, and write that its molecular targets “remain unknown”. We found no registered trial (ClinicalTrials.gov, 21 Nov 2026) |
T2 is small or uncontrolled human research, T3 is animal studies and T4 is cell studies: how we grade evidence. Full profiles: GHK-Cu, BPC-157, TB-500 and KPV.
05Has the KLOW mix been tested, and what is unknown?
Not in anything we found: no study gave the four together to cells, animals or people.
On 21 November 2026 we searched PubMed for papers naming all four components, with the names quoted and unquoted: none. Eight papers name GHK-Cu together with BPC-157, and each is a review, commentary or letter. No PubMed record uses KLOW as the name of a peptide mix. ClinicalTrials.gov lists no trial that gives two or more of the four together.
Studies of pairs exist, for example a 2026 rat study that had a group given BPC-157 and TB-500, and a 2026 report describes three patients given the same two with other agents and no control group. A pair is not the mix: peptide blends: one vial, no shared evidence.
What has not been shown
Any effect of the four together
We found no published study, in any species, and no registered trial that gave GHK-Cu, BPC-157, TB-500 and KPV together (PubMed and ClinicalTrials.gov, 21 Nov 2026).
That the four stay intact in one vial
Whether the peptides stay stable together, or change one another, is a separate question. We found no published data.
A safety record in people
FDA staff found no clinical studies or human exposure data for TB-500 or KPV, and “insufficient clinical safety information” for BPC-157. They wrote that BPC-157, given by injection or nasally, and TB-500, given by injection, “may pose a significant risk for immunogenicity”, the tendency to provoke an immune response. FDA says compounded injectable GHK-Cu “may pose risk for immunogenicity”, with “limited data in humans”.
What a given vial holds
A lab report shows only what the tested sample from that lot held, and only for the peptides it identifies and measures.
06Where does each component stand with regulators in the US, UK and Australia, and in sport?
Status attaches to each component, not to the name. Dated 21 November 2026.
The FDA lists, the HHS policy, Australia’s Poisons Standard and the WADA Prohibited List that we read do not name the mix. Each sets a status component by component. FDA’s drug database, Drugs@FDA, lists no drug containing any of the four.
| Component | United States | Australia | Sport (WADA 2026 and 2027 Lists) |
|---|---|---|---|
| GHK-Cu | On FDA’s 503A list it is in Category 1, substances under evaluation, “except for injectable routes of administration”. Not in HHS’s policy | The TGA says: “Most peptide products, including BPC-157, TB-500 and melanotan I, are prescription-only medicines in Australia.” No entry by name in the Poisons Standard October 2026, which has group entries for copper compounds. We draw no scheduling conclusion of our own | Not named. WADA says a peptide not specifically named “may still be prohibited” |
| BPC-157 | Out of FDA’s Category 2 since 22 April 2026. Named in HHS’s draft compounding policy of October 2026, which is not an approval | Schedule 4, prescription-only medicines, and Appendix D of the Poisons Standard October 2026 | Prohibited at all times; named in class S0 |
| TB-500 | Out of FDA’s Category 2 since 22 April 2026. Named in HHS’s draft compounding policy of October 2026, which is not an approval | Schedule 4 and Appendix D of the Poisons Standard October 2026; thymosin β4 has its own entry | Prohibited at all times; named in class S2.3 as a derivative of thymosin β4 |
| KPV | Out of FDA’s Category 2 since 22 April 2026. Named in HHS’s draft compounding policy of October 2026, which is not an approval | The TGA says: “Most peptide products, including BPC-157, TB-500 and melanotan I, are prescription-only medicines in Australia.” No entry by name in the Poisons Standard October 2026. We draw no scheduling conclusion of our own | Not named. WADA says a peptide not specifically named “may still be prohibited” |
United States. HHS’s policy applies only when the product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. HHS gives the reason: “It will be easier to attribute adverse events or clinical outcomes to a specific substance.” The Federal Register notice calls the policy a draft that “is not binding”. Background: the HHS peptide policy.
United Kingdom. The emc, a database of UK licensed-medicine information, returned no results for BPC-157, TB-500, thymosin, KPV, GHK, copper tripeptide or prezatide on 21 November 2026. It is not the full UK register. Under the Human Medicines Regulations 2012, whether a product is a medicinal product depends on how it is presented or on its “pharmacological, immunological or metabolic action” (regulation 2), and “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product” (regulation 46).
- Sep 2023FDA Category 2
BPC-157, TB-500 and KPV enter FDA’s list of compounding substances that raise significant safety risks. HHS records that they left it on 22 April 2026 and that neither step changed their status under section 503A.
- 14 May 2026GHK-Cu back under evaluation
FDA’s updated list returns GHK-Cu, except for injectable routes, to Category 1. FDA intends to consult its advisory committee on it before the end of February 2027.
- 23–24 Jul 2026Advisory committee meets
FDA staff propose not adding BPC-157, TB-500 or KPV to the 503A bulks list. HHS records that the committee voted in favour of each.
- 30 Oct 2026HHS draft policy published
It names six peptides, including BPC-157, TB-500 and KPV, for single-ingredient products only.
- 1 Jan 2027WADA 2027 List takes effect
Its S0 class adds “peptides” to its examples. BPC-157 and TB-500 remain named.
The dated tracker for every compound: regulatory status. Sport in detail: peptides and anti-doping.
07What should a lab report for a four-component vial show?
Everything a single-peptide report shows, four times over.
The eight checks for any certificate are on how to read a COA. A vial that lists four peptides adds four things.
Each peptide identified on its own, with its observed mass beside the expected one. FDA’s reviews give 1419.5 g/mol for BPC-157, 889.01 for TB-500 and 342.43 for KPV.
How much of each peptide the tested sample held. One total for the vial cannot show the split.
Purity is the main compound’s share of what the test detected. In a vial with four compounds, one percentage cannot show that each peptide is present.
The report describes one lot. If its number differs from the one on the vial, the document is about a different lot.
What a regulator found. The TGA’s laboratory reported “No TB-500 detected” in two KLOW products from one brand, identified in a New South Wales police investigation, whose labels listed TB-500 (advisory of 5 November 2026). Its conclusion: consumers cannot rely on these labels to know what substance, or what amount, a product contains. That advisory covers that brand only.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.